Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone therapy, comparable to Menarini's Orserdu.

John­son & John­son scored an ap­peals court win in its bid to block gener­ic com­pe­ti­tion for its long-act­ing schiz­o­phre­nia drug.

Ei­sai has slashed 2027 sales pro­jec­tions for its Bio­gen-part­nered Alzheimer’s treat­ment Leqem­bi by rough­ly half.

As­traZeneca is fur­ther in­vest­ing in Chi­na, open­ing an R&D cen­ter in Bei­jing and ink­ing a pair of ma­jor­ly back­loaded R&D deals with Chi­nese drug de­vel­op­ers … ...

Roche has forged a mul­ti­year part­ner­ship with Ox­ford Bio­Ther­a­peu­tics to find new tar­gets for an­ti­body-based can­cer treat­ments with an up­front pay­ment of $36 mil­lion.

Mehmet Oz has com­mit­ted to de­fend­ing Medicare drug price ne­go­ti­a­tions in court if he is con­firmed to lead CMS.

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

When End­points News launched our Health Tech newslet­ter in Fall 2023, it was the first time our news­room had stepped out­side the world of bio­phar­ma … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Di­men­sion has crossed a key thresh­old. The VC firm’s trio of New York and Bay Area man­ag­ing part­ners has raised a sopho­more fund in the … ...

The Biden Ad­min­is­tra­tion said Wednes­day that it has se­cured agree­ments with Ver­tex Phar­ma­ceu­ti­cals and blue­bird bio for their sick­le cell dis­ease gene ther­a­pies ...

Now that Pres­i­dent-elect Don­ald Trump has made his choice for FDA com­mis­sion­er, re­ac­tions and analy­sis are pour­ing in from bio­phar­ma ex­ec­u­tives and for­mer staffers ...